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OBJECTIVES We sought to assess the safety and efficacy of pressure-guided nonsurgical myocardial
reduction (NSMR) with the induction of small septal infarctions in patients with hypertro-
phic obstructive cardiomyopathy (HOCM).
BACKGROUND Nonsurgical myocardial reduction has been shown to decrease left ventricular outflow tract
(LVOT) obstruction and to improve symptoms in patients with HOCM. Infarct sizes differ
considerably among studies published so far.
METHODS In 50 patients, the LVOT gradient was invasively determined at the time of the intervention,
four to six months (n 5 49) and 12 to18 months (n 5 25) after NSMR. New York Heart
Association functional class and quality of life were assessed by using a standard question-
naire. Exercise capacity was tested by spiro-ergometry. Left ventricular (LV) mass was
determined by electron beam computed tomography.
RESULTS Small septal infarctions (mean creatine kinase value 413 6 193 U/l) resulted in a sustained
decrease in LVOT gradients, from 80 6 33 to 18 6 17 mm Hg after four to six months (p ,
0.001, n 5 49) and to 17 6 15 mm Hg (p , 0.001, n 5 25) after 12 to 18 months.
Nonsurgical myocardial reduction was followed by a decrease in LV hypertrophy, which was
associated with a sustained increase in exercise capacity, as well as improvement in quality of
life.
CONCLUSIONS Pressure-guided NSMR inducing small septal infarctions was sufficient to result in a sustained
decrease in LVOT obstruction and to improve symptoms. The incidence of complications,
such as complete heart block with necessary permanent pacemaker implantation (,10%),
seems to be diminished by minimizing the infarct size. (J Am Coll Cardiol 2001;38:846–53)
© 2001 by the American College of Cardiology
Hypertrophic obstructive cardiomyopathy (HOCM) is
characterized by a slowly increasing asymmetric septal
hypertrophy, which can lead to dynamic left ventricular
outflow tract (LVOT) obstruction (1,2). As a consequence,
progressive systolic and diastolic left ventricular (LV) dys-
function may develop (1–3), leading to dyspnea, angina,
arrhythmias and even sudden cardiac death. Nonsurgical
myocardial reduction (NSMR) of septal hypertrophy has
recently been shown to decrease LVOT obstruction and to
improve symptoms in patients with HOCM (4–8).
Nonsurgical myocardial reduction is accomplished by a
septal infarction, which reduces or abolishes LVOT ob-
struction (9). In the majority of studies, ethanol has been
used to induce septal infarction (4–10). However, the
amount of ethanol injected (1 to 6 ml) and, thus, infarct
size, as reflected by the increase in creatine kinase (CK),
differ considerably among the studies published so far (4–9).
The impact of large infarct sizes (6,11) on the long-term
outcome of these patients has not been determined. How-
ever, it might provide a substrate for the development of
life-threatening ventricular arrhythmias, similar to patients
who have had a myocardial infarction. Furthermore, there is
evidence that the early incidence of complications, such as
complete heart block with necessary pacemaker implanta-
tion, is influenced by the amount of ethanol injected during
the procedure (6,7). Whether other factors, such as the
speed of ethanol injection, are related to the incidence of
complications has not been systematically investigated so
far.
Therefore, we tried to keep the infarct sizes as small as
possible by reducing the amount of ethanol injected per
septal branch at the beginning of this study (10). After
following pressure-guided criteria, as suggested by the initial
clinical applications of the procedure (9,12), we report here
on the short- and long-term results, as well as the compli-
cation rates, of a pressure-guided approach to NSMR
aiming at the minimal required size of septal infarctions.
METHODS
Study group. Fifty patients (age 55 6 14 years; 25 men and
25 women) with symptomatic HOCM (New York Heart
Association [NYHA] functional class 2.8 6 0.6) and an
echocardiographically determined LVOT gradient
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$30 mm Hg at rest were enrolled into this study between
September 1996 and December 1999.
All patients gave written, informed consent at least 24 h
before the intervention, after the primary investigator (P.B.)
provided the patients with detailed information on the
different therapeutic options and the risk of the procedure.
The patients’ histories included pulmonary edema (n 5
17), syncope (n 5 18), stroke (n 5 1) and survival of sudden
cardiac death (n 5 1). Thirteen patients were treated with
beta-blockers and 26 patients with verapamil before
NSMR. Significant coronary artery disease was detected in
four patients and treated by single-vessel stent implantation.
Four to six months later, these patients were enrolled for
NSMR after restenosis at the stent site, as well as progres-
sion of coronary artery disease, had been excluded.
Noninvasive evaluation. For assessment of quality of life,
all patients answered a standardized questionnaire (SF-12)
(13) before and 28 days, four to six months and 12 to 18
months after NSMR. The NYHA functional class was
determined at the same time.
CARDIOPULMONARY EXERCISE TESTING. An incremental
symptom-limited cardiopulmonary exercise test was per-
formed in 32 of 50 patients, as described in detail previously
(14). Eight patients who were in NYHA functional class IV
did not tolerate cardiopulmonary exercise testing. In addi-
tion, seven patients underwent previous cardiac catheteriza-
tion in another hospital within seven days before the
intervention and were not eligible for exercise testing.
Because the anaerobic threshold was not reached in another
seven patients, the final analysis included only 25 of 50
patients. Cardiopulmonary exercise tests were performed
before NSMR, 7 days, 4 to 6 months and 12 to 18 months
after the procedure.
LEFT VENTRICULAR HYPERTROPHY. For determination of
myocardial mass, an Imatron C-150 Scanner (Siemens,
Germany), with an acquisition time of 100 ms at a spatial
resolution of 0.7 mm2, was used. After injecting 70 ml of
nonionic contrast agent into the right cubital vein, 20
images were recorded during each cardiac cycle. Starting at
the aortic valve, eight slices (3-mm thick) were acquired
from the basis to the apex of the heart. Epicardial and
endocardial borders were marked manually, and the myo-
cardial area of each slice was determined. This area was
divided into 12 segments, and the volume and myocardial
mass (specific gravity 1.05 g/cm3) were calculated for each
segment (15–17). Two septal segments of each of the first
four slices (eight segments total) were taken to estimate
septal mass. Correspondingly, two segments of the con-
tralateral wall of the same four slices were taken to calculate
the volume of eight lateral segments. Follow-up was ob-
tained at seven days (n 5 50), four to six months (n 5 49)
and 12 to 18 months (n 5 25) after NSMR.
Invasive procedures and NSMR by ethanol. All patients
(n 5 50) underwent coronary angiography before NSMR.
In 40 of the 50 patients, invasive electrophysiologic testing
was performed before and four to six months after NSMR
to determine the patients’ susceptibility to ventricular ar-
rhythmias before and after NSMR. As the majority of the
patients did not have a history of ventricular arrhythmia or
survival of sudden cardiac death, a single-site electrophysi-
ologic test was chosen to prevent nonspecific ventricular
fibrillation, which is known to occur with more aggressive
protocols in patients with HOCM (8). Thus, programmed
ventricular stimulation at a single site within the right
ventricular apex, using a basal cycle length of 600, 500, 400
and 333 ms, with up to two premature beats, was analyzed
to determine the induction of ventricular runs, ventricular
tachycardia or ventricular fibrillation. Thereafter, the pacing
catheter remained in the right ventricle for delivery of
premature beats to determine the post-extrasystolic LVOT
gradient and for back-up pacing in case of complete heart
block after NSMR.
After exclusion of aortic valve stenosis, the LVOT
gradient was continuously monitored. For measurement of
LV pressure, a 6F pigtail catheter was advanced by using a
retrograde approach and placed distally to the intraventric-
ular obstruction in the LV. Aortic pressure was determined
simultaneously by using a 7F guiding catheter with side
holes (Judkins L4, Cordis). The systolic LVOT gradient
was determined at rest and after a programmed premature
beat. Hemodynamic variables, including LVOT gradient
and LV end-diastolic pressure (LVEDP), were analyzed at
baseline, during balloon occlusion of the target septal
branch and 20 min after ethanol injection. Invasive hemo-
dynamic measurements were repeated after four to six
months (n 5 49) and 12 to 18 months (n 5 25).
In all patients, NSMR was guided exclusively by contin-
uous monitoring of the LVOT gradient, as originally
suggested by Sigwart (9). After intravenous delivery of
10,000 IU of heparin, a 0.014-in. (0.035-cm) guide wire
was selectively placed in the presumed culprit septal branch,
which was chosen only if it was of sufficient size (presumed
diameter $1.5 mm) and length ($2 cm). Thereafter, an
over-the-wire angioplasty balloon (1.5 mm in diameter and
15 mm in length or 2.0 mm in diameter and 20 mm in
length; Takumi, Schneider, Switzerland) was placed in the
target septal branch. After balloon inflation (4 to 6 atm),
correct placement was verified by injection of contrast agent
into the left coronary artery and then into the septal branch
Abbrevations and Acronyms
ANOVA 5 analysis of variance
CK 5 creatine kinase
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LV 5 left ventricle, left ventricular
LVEDP 5 left ventricular end-diastolic pressure
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LVOT 5 left ventricular outflow tract
NSMR 5 nonsurgical myocardial reduction
NYHA 5 New York Heart Association
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distal to the balloon catheter, avoiding retrograde leakage
along the balloon at the same time. Moreover, injection of
contrast agent under fluoroscopic guidance in at least two
projections allowed estimation of the extent of myocardium
supplied by the septal branch, as well as detection of
shunting from the septal branch to nontargeted myocardial
regions, such as the lateral LV wall.
Subsequent ethanol injection was performed only if the
LVOT gradient at rest decreased .30 mm Hg or
.50 mm Hg after a programmed premature beat during
occlusion of the septal branch, with or without injection of
contrast agent. If these pressure-guided criteria were not
met, the balloon was deflated and the procedure was
repeated using a different septal branch (n 5 11). If the
pressure-guided criteria were fulfilled, 96% ethanol was
injected into this septal branch. The first milliliter of
ethanol was injected rapidly (mean injection time 7 6 4 s),
depending on the diameter of the balloon (1.5 up to
2.5 mm). The rest of the ethanol (0.5 to 1.0 ml) was slowly
injected during 30 s. In four patients, the LVOT gradient
was abolished completely after injection of 1 ml of ethanol,
so that no further ethanol was administered. Otherwise, a
total amount of 1.5 to 2.0 ml of ethanol was injected into a
single septal branch, depending on the size of the vessel.
The hemodynamic result was considered satisfactory if the
LVOT gradient at rest or after a programmed premature
beat was reduced by .50%. After ethanol injection and
removal of the balloon, the LVOT gradient increased by
.30 mm Hg in three patients. After choosing a more
proximal position of the balloon in the same septal branch,
re-injection of 1 ml of ethanol was followed by a satisfactory
reduction in the LVOT gradient in all three patients. More
recently, with shorter balloons becoming available for the
NSMR procedure, occlusion of side branches was avoided.
If the LVOT gradient after ethanol injection into a single
septal branch was still .50% of the baseline value, a second
or third septal branch was selected and injected (two
branches in four patients and three branches in two pa-
tients).
Post-interventional monitoring was done at an intensive
care unit for 12 to 24 h. Creatine kinase was determined
every 4 h. The temporary pacemaker was left in place for 24
to 96 h only if complete heart block was present after
NSMR. Otherwise, it was removed 30 min after the
procedure.
Statistical analysis. All data are presented as the mean
value 6 SD and were analyzed using SPSS statistical
software. Repeated measurements of continuous variables
were compared by one-way analysis of variance (ANOVA).
Subsequent Bonferroni correction was used to adjust for
multiple testing. For repeated determinations of quality-of-
life scores, nonparametric one-way ANOVA (Kruskal-
Wallis) was used. If the result was statistically significant
(p , 0.05), comparison between time points was done using
the Mann-Whitney U test. A p value ,0.05 was considered
statistically significant. Correlations between peak CK levels
and the volume of ethanol injected and between peak CK
levels and LVOT reduction were evaluated using Pearson’s
correlation coefficient.
RESULTS
Infarct size and complications of the procedure. A mean
of 1.2 6 0.4 septal branches were ablated by injection of
1.9 6 0.7 ml of ethanol in 50 patients. The mean peak rise
in CK was 413 6 193 U/l (range 179 to 1,019). A single
septal branch was injected by only 1.7 6 0.5 ml of ethanol
(mean CK 367 6 158 U/l) in 44 patients (88%). In 39
patients (78%), balloon occlusion of the septal branch,
initially approached for anatomic reasons, provided a suffi-
cient reduction in the LVOT gradient to meet the pressure-
guided criteria, and the septal branch was subsequently
injected with ethanol. For all 50 patients, there was a close
correlation (r 5 0.74, p , 0.001) between the volume of
ethanol injected and the peak CK level, whereas no rela-
tionship (r 5 20.03) existed between the peak CK level and
the reduction in the LVOT gradient.
Transient complete heart block after ethanol injection oc-
curred in 18 (36%) of 50 patients. In all of these patients,
complete heart block resolved within 12 h. However, recurrent
transient complete heart block was observed in 5 (10%) of 50
patients within seven days after the procedure, necessitating
implantation of a permanent DDD-pacemaker for safety
reasons. No other periprocedural complications occurred, and
no patient died during the hospital stay. The patients remained
in the hospital for at least seven days after the procedure (mean
7.5 6 0.7 days). One patient with concomitant coronary artery
disease who underwent stent implantation three months before
NSMR died of an acute myocardial infarction five months
after the procedure. No major cardiac event was observed in
any of the other 49 patients during the follow-up period up to
40 months.
Short- and long-term hemodynamic results. In 50 pa-
tients, the mean rest LVOT gradient significantly decreased
from 80 6 33 to 45 6 32 mm Hg (p , 0.001) during
balloon inflation of the target septal branch. Subsequent
ethanol injection was followed by an immediate further
reduction in the rest LVOT gradient to 18 6 13 mm Hg,
associated with a decrease in the post-extrasystolic gradient
from 154 6 40 to 53 6 40 mm Hg (p , 0.001) (Fig. 1).
Invasive hemodynamic measurements at four to six months
(n 5 49) and 12 to 18 months of follow-up (n 5 25)
showed a sustained decrease in the rest and post-
extrasystolic LVOT gradient (Fig. 1). Although LVEDP
did not change significantly immediately after NSMR
(23 6 7 to 20 6 10 mm Hg), there was a highly significant
reduction in LVEDP four to six months (13 6 7 mm Hg,
n 5 49, p , 0.001) and 12 to 18 months (12 6 8 mm Hg,
n 5 25, p , 0.001) after the procedure.
Left ventricular hypertrophy. To quantify LV hypertro-
phy (LVH) after NSMR, LV mass was determined by
electron beam computed tomography (15–17). As expected,
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septal mass decreased within seven days after NSMR
(28.7 6 3.4 to 24.9 6 3.4 g, n 5 50, p , 0.001), whereas
no change in the mass of the contralateral wall could be
detected at that time (Fig. 2). After four to six months,
however, a significant decrease in the contralateral wall
mass, from 21.3 6 2.3 to 16.9 6 2.2 g (n 5 49, p , 0.001),
was observed. Long-term follow-up after 12 to 18 months
showed a sustained decrease in septal (29.3 6 3.6 to 19.1 6
4.0 g, n 5 25, p , 0.001) and contralateral wall mass
(21.4 6 2.8 to 14.4 6 2.5 g, n 5 25, p , 0.001). The mass
of all 64 LV segments analyzed decreased by 17% after four
to six months (n 5 49, p , 0.001) and by 28% after 12 to
18 months (n 5 25, p , 0.001) (Fig. 2).
Cardiopulmonary exercise capacity. Exercise capacity in-
creased early (7 days) after NSMR, but showed a pro-
nounced further increase after four to six months (n 5 25)
and 12 to 18 months (n 5 25) (Fig. 3). Furthermore, there
was a parallel increase in peak oxygen consumption. The
anaerobic threshold, however, did not change after seven
days, but significantly increased four to six months and 12
to18 months after NSMR (Fig. 3).
Quality of life. Improvement of quality of life was dem-
onstrated by a decrease in the score, from 31 6 8 to 26 6
8 points after 28 days and to 25 6 9 points after four to six
months (p , 0.01) post-NSMR. Concomitantly, the
NYHA functional class decreased from 2.8 6 0.6 to 2.0 6
0.6 after 28 days and to 1.9 6 0.7 after four to six months
(p , 0.001) post-NSMR. Two years after NSMR (n 5 25),
the score data (25 6 7 points) and functional class (1.7 6
0.7) confirmed the sustained improvement in quality of life
(Fig. 4).
Electrophysiologic studies. To assess the patients’ suscep-
tibility to ventricular arrhythmias, electrophysiologic testing
was performed in 39 patients before and four to six months
after NSMR. The incidence of inducible ventricular tachy-
cardia or ventricular fibrillation (2/3933/39) and ventricu-
lar beats or runs (6/3932/39), as well as clinical events
(survival of sudden cardiac death: 1/3931/39), did not
change after NSMR. As expected, more than half of the
patients (4/39322/39) had complete right bundle branch
block after the procedure, with prolongation of the QRS
duration from 96 6 12 to 125 6 43 ms (p , 0.05).
DISCUSSION
Nonsurgical myocardial reduction by ethanol ablation has
recently been shown to decrease LVOT obstruction and to
improve symptoms in patients with HOCM (4–8). The
anatomic substrate for the LVOT obstruction is a relative,
distinct narrowing between the thickened septum and the
mitral valve leaflet (18). Because septal muscle contraction
might also contribute to LVOT obstruction, large infarct
sizes have been induced in the first series of patients with
HOCM treated by NSMR (4,6,9). Infarct size, as estimated
by the rise in CK after NSMR, was substantially lower (peak
CK 413 6 193 U/l) in our study than in the reports by other
groups (4–8), with a range of peak CK from 676 6 347 (7)
to 1,964 6 796 U/l (6).
Figure 1. Invasively determined left ventricular outflow tract (LVOT) gradient before, immediately after, four to six months after and 12 to 18 months after
nonsurgical myocardial reduction. *p , 0.001 compared with baseline. n.s. 5 statistically nonsignificant.
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Impact of smaller infarct size on hemodynamic variables
and clinical improvement. The main result of the present
study was that rather small but correctly localized infarctions
were sufficient to reduce the LVOT gradient to a similar
extent as that described by the groups of investigators
inducing larger infarct sizes (4–8). Considering the studies
published so far with invasive determination of LVOT
gradients (4,5,7,8), the reduction in the LVOT gradient at
rest (D62 mm Hg) and the remaining pressure gradient after
NSMR (18 6 13 mm Hg) observed in our study was
comparable to the data reported by other groups (D42 respec-
tively 19 6 21 mm Hg [5]; D57 respectively 17 6 18 mm Hg
[7]; D43 respectively 8 6 5 mm Hg [4]; D45 respectively 12 6
3 mm Hg [8]). In another study using Doppler measurements
(6), the reduction in the pressure gradient was D37 mm Hg
and remaining rest gradient was 12 6 12 mm Hg.
Furthermore, long-term invasive hemodynamic follow-up
of 12 to 18 months showed a sustained reduction in the
intraventricular pressure gradient in our patients (Fig. 1),
which was accompanied by a significant clinical improvement
(Fig. 3). With regard to NYHA functional class improvement
after NSMR, the published data range from 1.7 6 0.6 (8) to
0.9 6 0.6 (6). Improvement in functional class after NSMR
appeared to be somewhat less pronounced in our study (1.9 6
0.7 after four to six months and 1.7 6 0.7 after 12 to 18
months). As functional class is a subjective measure, the
differences in assessment and patient population may influence
the results. The clinical improvement of our patients was also
confirmed by the increase in cardiopulmonary exercise capac-
ity, as well as the increase in maximal oxygen consumption and
anaerobic threshold (Fig. 4).
Impact of smaller infarct sizes on LVH. Another impor-
tant issue addressed by serial studies using electron beam
computed tomography was the effect of NSMR on the
development of LVH. Ultrafast computed tomography has
a high accuracy and reproducibility (i.e., low intraobserver
and interobserver variabilities) with regard to the assessment
of LV mass (17). As expected, there was a decrease in the
septal mass due to the ethanol ablation seven days after
NSMR, whereas the contralateral wall and the total LV
mass were not different at that time (Fig. 2). As already
described by other groups using echocardiography (6,7), the
Figure 2. Development of left ventricular hypertrophy after nonsurgical myocardial reduction. Septal segments 5 volume of eight septal segments;
contralateral segments 5 volume of eight segments of the lateral wall; total segments 5 volume of 64 segments. *p , 0.001 compared with baseline.
n.s. 5 statistically nonsignificant.
850 Boekstegers et al. JACC Vol. 38, No. 3, 2001
Small Septal Infarctions in HOCM September 2001:846–53
contralateral wall and total LV mass significantly decreased
after four to six months and 12 to 18 months, indicating
that NSMR was followed by a sustained regression in LVH.
Thus, similar to the reduction in pressure-induced LVH
after aortic valve replacement (19), LVH decreased after
NSMR. Apparently, these beneficial effects on LVH were
present in our patients with rather small infarctions after
NSMR.
Impact of smaller infarct size on complications and
ventricular arrhythmias. The incidence of temporary
(36%) and permanent complete heart block (0%), as well as
permanent pacemaker implantation (10%), was rather low
in our first group of 50 patients, compared with studies of
patients with larger infarctions with a higher incidence of
temporary (range 52% to 70%) (5,7,8) and permanent
complete heart block (range 4% to 33%) (6–8), as well as
subsequent pacemaker implantation (range 11% to 38%)
(5–8). Furthermore, the susceptibility to ventricular ar-
rhythmias did not change in the follow-up period of four to
six months, as estimated from electrophysiologic testing and
clinical events, which is in agreement with a previous study
(8). Although we observed one death five months after
NSMR, it was not related to the procedure, because the
patient had concomitant coronary artery disease and died of
an acute myocardial infarction. Therefore, the overall inci-
dence of complications was acceptable, particularly with
regard to the clinical improvement of our patients. From the
invasive long-term hemodynamic measurements, as well as
the subjective and objective measures of clinical improve-
ment, we infer that small infarct sizes appear to be as
effective as large infarct sizes for NSMR, but might be
associated with a lower incidence of complications in the
treatment of patients with HOCM.
Identification of the culprit septal branch. As the infarct
size induced by ethanol injection is likely to be dependent
on the amount of ethanol injected (4,5,20), we restricted it
to a maximum of 2 ml per septal branch when we started
this study in September 1996 (10). Indeed, the present study
demonstrates a close correlation between the amount of
ethanol injected and the maximal rise in CK levels as an
estimate of infarct size, similar to the observations by other
groups (5,7). However, there was no evidence that higher
Figure 3. Cardiopulmonary exercise testing before and after nonsurgical myocardial reduction. Peak VO2 5 peak oxygen consumption; AT 5 anaerobic
threshold. *p , 0.001 compared with baseline. n.s. 5 statistically nonsignificant.
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CK levels were associated with a greater reduction in the
intraventricular pressure gradient, not even in those patients
with ethanol injection into more than one septal branch.
To minimize the amount of ethanol required and, corre-
spondingly, the size of the septal infarction, identification of
the culprit septal branch appears to be of crucial importance.
There is an ongoing discussion with regard to the best
available technique to identify the culprit septal branch
(6,7,21). Recently, intraprocedural myocardial contrast
echocardiography has been suggested to define the extent
and localization of the induced septal necrosis more pre-
cisely than pressure guidance (6,7). Despite similar use of
intraprocedural myocardial contrast echocardiography, large
infarctions (mean CK 1,964 6 796 U/l) associated with a
high rate of complete heart block after the procedure have
been reported in one of these studies (6). The main
difference between these two studies (6,7), however, was the
amount of ethanol injected and the number of septal
branches ablated. Therefore, these two factors seem to be
more important than the use of myocardial contrast echo-
cardiography. Other arguments to use intraprocedural con-
trast echocardiography appear reasonable at first glance,
such as the identification of a septal branch supplying the
lateral LV wall or a papillary muscle. Whether the incidence
of such complications is actually reduced by echocardio-
graphic guidance has never been demonstrated. Using
pressure-guided criteria and the injection of low amounts of
ethanol, we have never experienced procedural or clinical
complications, indicating lateral wall or papillary muscle
injections in .70 patients up to now. In addition, careful
fluoroscopic examination of the passage of the contrast
agent selectively injected into the septal branch might also
help to avoid subsequent misinjection of ethanol.
Conclusions. Our study supports the assumption that
restricting the amount of ethanol injected is more impor-
tant, to reduce infarct size and complications of the proce-
dure, than the technique used for the identification of the
culprit septal branch. More than one septal branch was
injected in only six patients showing several small septal
branches. This might also reflect overlapping regions sup-
plying the target myocardium responsible for the LVOT
obstruction, rather than misidentification of the culprit
septal branch. From these observations, we conclude that
the anatomy and accessibility of the septal branches supply-
ing the target area of NSMR is another important factor
influencing the results of the procedure, which seem to be
independent of the technique (21) used for the identifica-
tion of the culprit septal branch.
Reprint requests and correspondence: Dr. Peter Boekstegers,
Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians-
University, 81366 Munich, Germany. E-mail: boekstegers@
med1.med.uni-muenchen.de.
REFERENCES
1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hyper-
trophic cardiomyopathy: interrelations of clinical manifestations,
pathophysiology, and therapy (first of two parts). N Engl J Med
1987;13:780–9.
2. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hyper-
trophic cardiomyopathy: interrelations of clinical manifestations,
pathophysiology, and therapy (second of two parts). N Engl J Med
1987;14:844–52.
3. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomy-
opathy: the importance of the site and the extent of hypertrophy—a
review. Prog Cardiovasc Dis 1985;1:1–83.
4. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal
Figure 4. Functional classes (New York Heart Association [NYHA]) and quality of life scores, determined from a standard questionnaire before and after
nonsurgical myocardial reduction. *p , 0.001 compared with baseline. n.s. 5 statistically nonsignificant.
852 Boekstegers et al. JACC Vol. 38, No. 3, 2001
Small Septal Infarctions in HOCM September 2001:846–53
reduction for hypertrophic obstructive cardiomyopathy: outcome in
the first series of patients. Circulation 1997;95:2075–81.
5. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK,
Strick S. Percutaneous transluminal septal myocardial ablation in
hypertrophic obstructive cardiomyopathy: acute results and 3-month
follow-up in 25 patients. J Am Coll Cardiol 1998;31:252–8.
6. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided
ethanol septal reduction for hypertrophic obstructive cardiomyopathy.
Circulation 1998;98:1750–5.
7. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal
septal myocardial ablation in hypertrophic obstructive cardiomyopathy:
results with respect to intraprocedural myocardial contrast echocardi-
ography. Circulation 1998;98:2415–21.
8. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-
term results after transcoronary ablation of septum hypertrophy
(TASH): a catheter interventional treatment for hypertrophic obstruc-
tive cardiomyopathy. Eur Heart J 1999;20:1342–54.
9. Sigwart U. Non-surgical myocardial reduction for hypertrophic ob-
structive cardiomyopathy. Lancet 1995;346:211–4.
10. Boekstegers P, Steinbigler P, Schwaiblmair M, et al. Transcoronary
ablation of septal hypertrophy (TASH) inducing smaller infarctions
shows similar hemodynamic and clinical effects (medium-term follow-
up) but a low complication rate in patients with hypertrophic obstruc-
tive cardiomyopathy (abstr). Circulation 1998;17 Suppl I:I444.
11. Spirito P, Maron BJ. Perspectives on the role of new treatment
strategies in hypertrophic obstructive cardiomyopathy. J Am Coll
Cardiol 1999;4:1071–5.
12. Kuhn H, Gietzen F, Leuner Ch, Gernkamp T. Induction of subaortic
septal ischemia to reduce obstruction in hypertrophic obstructive
cardiomyopathy: studies to develop a new catheter based concept of
treatment. Eur Heart J 1997;18:846–51.
13. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health
Survey (SF-36): I. Conceptual framework and item selection. Med
Care 1992;30:473–83.
14. Schwaiblmair M, von Scheidt W, U¨berfuhr P, Reichart B, Vogelmeier
C. Lung function and cardiopulmonary exercise performance after
heart transplantation: influence of cardiac allograft vasculopathy. Chest
1999;116:332–9.
15. Feiring A, Rumberger JA, Reiter SJ, et al. Determination of left
ventricular mass in dogs with rapid-aquisition cardiac computed
tomographic scanning. Circulation 1985;6:1355–64.
16. Hajduczok ZD, Weiss RM, Stanford W, Marcus ML. Determination
of right ventricular mass in humans and dogs with ultrafast cardiac
computed tomography. Circulation 1990;82:202–12.
17. Roig E, Georgiou D, Chomka E, et al. Reproducibility of left
ventricular myocardial volume and mass measurements by ultrafast
computed tomography. J Am Coll Cardiol 1991;18:990–6.
18. Nagata S, Nimura Y, Beppu S, Park YD, Sakakibara H. Mechanism
of systolic anterior motion of mitral valve and site of interventricular
pressure gradient in hypertrophic obstructive cardiomyopathy. Br
Heart J 1983;49:234–43.
19. Hess O, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic
stenosis. Ciculation 1993;87 Suppl IV:IV73–6.
20. Gleichmann U, Seggewiss H, Faber L, Fassbender D, Schmidt HK,
Strick S. Kathetertherapie der hypertrophen obstruktiven Kardiom-
yopathie. Dtsch Med Wochenschr 1996;21:679–85.
21. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH) in
HOCM: a five-year experience. Z Kardiol 2000;89:559–64.
853JACC Vol. 38, No. 3, 2001 Boekstegers et al.
September 2001:846–53 Small Septal Infarctions in HOCM
